<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> are acquired circulating immunoglobulins that interact with <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>These factors may manifest <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> properties in vitro, interfering with <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-dependent coagulation tests </plain></SENT>
<SENT sid="2" pm="."><plain>They are not, however, associated with a <z:e sem="disease" ids="C0019087" disease_type="Disease or Syndrome" abbrv="">hemorrhagic diathesis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Indeed, far from exerting the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> properties they possess in vitro, they are associated with episodes of <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, systemic and cerebral </plain></SENT>
<SENT sid="4" pm="."><plain>We report the clinical and instrumental findings in 7 patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and circulating <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> classifiable as <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> syndrome </plain></SENT>
</text></document>